Pear Therapeutics president and CEO Corey McCann (Pear)
Pear Therapeutics nabs $80M Series D to commercialize three digital therapeutics
As the pandemic rages on, virtual care options have investors champing at the bit. Boston-based Pear Therapeutics is the latest to benefit, reeling in $80 million to commercialize its three prescription digital therapeutics.
The digital therapeutics umbrella encompasses technology like mobile apps and telemedicine platforms designed to prevent, treat or manage disease. Some are used alone, while others are combined with medication.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters